efficacy of Donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on Caregiver burden
Identifieur interne : 000F24 ( PascalFrancis/Curation ); précédent : 000F23; suivant : 000F25efficacy of Donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on Caregiver burden
Auteurs : Howard Feldman [Canada] ; Serge Gauthier [Canada] ; Jane Hecker [Australie] ; Bruno Vellas [France] ; Birol Emir [États-Unis] ; Vera Mastey [États-Unis] ; Ponni Subbiah [États-Unis]Source :
- Journal of the American Geriatrics Society [ 0002-8614 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Personne âgée.
English descriptors
- KwdEn :
Abstract
OBJECTIVES: This study investigated the efficacy of donepezil treatment on activities of daily living (ADLs) and social functioning in patients with moderate to severe Alzheimer's disease (AD) and the possible benefits of this treatment on caregiving time and stress levels. DESIGN: Randomized, double-blind, placebo-controlled, multinational study. SETTING: Patients resided in the community or in assisted living facilities who did not require skilled 24-hour nursing care. PARTICIPANTS: Two hundred ninety patients with moderate to severe AD (baseline standardized Mini-Mental State Examination score of 5-17). INTERVENTION: Donepezil (5 mg/d for 4 weeks and 10 mg/d per clinician's judgment thereafter) or placebo for 24 weeks. MEASUREMENTS: ADLs were assessed using the Disability Assessment for Dementia (DAD), the modified instrumental activities of daily living (IADL) scale (IADL+), and the modified Physical Self Maintenance Scale (PSMS+). Caregiver time spent assisting patients with basic and instrumental ADLs was recorded as part of the IADL+ and PSMS+ scales. Patients' social behavior was evaluated through the use of a caregiver diary that captured observations of patients' motivation, interactions, and engagement. Caregivers were evaluated for their levels of caregiver stress with a modified, multiple-item Caregiver Stress Scale (CSS). For each outcome measure, the mean change from baseline at Week 24 using a last observation carried forward (LOCF) analysis was calculated. RESULTS: IADL+ and PSMS+ mean change from baseline scores for donepezil-treated patients showed a slower decline during the study than placebo-treated patients (Week 24 LOCF mean treatment differences: IADL + = 6.83, P <.0001; PSMS+ = 1.32, P =.0015). Significant differences between the groups in favor of donepezil were observed on the DAD for instrumental and basic ADLs and on the three components required for the completion of each ADL: initiation, planning and organization, and effective performance. At baseline, caregivers of patients treated with donepezil (n = 141) did not differ significantly from caregivers of patients treated with placebo (n = 146) with respect to demographics or mean total scores on the CSS. At Week 24 LOCF, the overall distribution of caregiver ratings on each of the three caregiver diary items favored donepezil-treated patients over placebo-treated patients (P <.005). At Week 24 LOCF, mean change from baseline scores for CSS total and individual domain scores (all domains except caregiving competence, personal gain, and management of distress) were better for caregivers of donepezil-treated patients than for those of placebo-treated patients (CSS total, mean treatment difference = 1.82). Caregivers of donepezil-treated patients reported spending less time assisting with ADLs than caregivers of placebo-treated patients (mean difference = 52.4 min/d). CONCLUSION: Donepezil demonstrated a significantly slower decline than placebo in instrumental and basic ADLs in these patients with moderate to severe AD. The ADL benefits in AD patients treated with donepezil were associated with less caregiving time and lower levels of caregiver stress.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005202
Links to Exploration step
Pascal:03-0440479Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">efficacy of Donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on Caregiver burden</title>
<author><name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, UBC Hospital, Clinic for Alzheimer's Disease and Related Disorders</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Alzheimer Disease Research Unit, McGill Center for Studies in Aging</s1>
<s2>Verdun, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Rehabilitation and Aged Care, Repatriation General Hospital</s1>
<s2>Daw Park, SA</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Toulouse University Alzheimer's Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Emir, Birol" sort="Emir, Birol" uniqKey="Emir B" first="Birol" last="Emir">Birol Emir</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Clinical Data Operations</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mastey, Vera" sort="Mastey, Vera" uniqKey="Mastey V" first="Vera" last="Mastey">Vera Mastey</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Clinical Data Operations and Outcomes Research, Pfizer, Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbiah, Ponni" sort="Subbiah, Ponni" uniqKey="Subbiah P" first="Ponni" last="Subbiah">Ponni Subbiah</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Clinical Data Operations and Pfizer Pharmaceuticals Group, Pfizer, Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0440479</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0440479 INIST</idno>
<idno type="RBID">Pascal:03-0440479</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">005202</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000F24</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">efficacy of Donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on Caregiver burden</title>
<author><name sortKey="Feldman, Howard" sort="Feldman, Howard" uniqKey="Feldman H" first="Howard" last="Feldman">Howard Feldman</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Neurology, UBC Hospital, Clinic for Alzheimer's Disease and Related Disorders</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Gauthier, Serge" sort="Gauthier, Serge" uniqKey="Gauthier S" first="Serge" last="Gauthier">Serge Gauthier</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Alzheimer Disease Research Unit, McGill Center for Studies in Aging</s1>
<s2>Verdun, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Hecker, Jane" sort="Hecker, Jane" uniqKey="Hecker J" first="Jane" last="Hecker">Jane Hecker</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Rehabilitation and Aged Care, Repatriation General Hospital</s1>
<s2>Daw Park, SA</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Vellas, Bruno" sort="Vellas, Bruno" uniqKey="Vellas B" first="Bruno" last="Vellas">Bruno Vellas</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Toulouse University Alzheimer's Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Emir, Birol" sort="Emir, Birol" uniqKey="Emir B" first="Birol" last="Emir">Birol Emir</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Clinical Data Operations</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Mastey, Vera" sort="Mastey, Vera" uniqKey="Mastey V" first="Vera" last="Mastey">Vera Mastey</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Clinical Data Operations and Outcomes Research, Pfizer, Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Subbiah, Ponni" sort="Subbiah, Ponni" uniqKey="Subbiah P" first="Ponni" last="Subbiah">Ponni Subbiah</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Clinical Data Operations and Pfizer Pharmaceuticals Group, Pfizer, Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of the American Geriatrics Society</title>
<title level="j" type="abbreviated">J. Am. Geriatr. Soc.</title>
<idno type="ISSN">0002-8614</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of the American Geriatrics Society</title>
<title level="j" type="abbreviated">J. Am. Geriatr. Soc.</title>
<idno type="ISSN">0002-8614</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetylcholinesterase</term>
<term>Activity</term>
<term>Alzheimer disease</term>
<term>Anticholinesterase agent</term>
<term>Caregiver</term>
<term>Daily living</term>
<term>Donepezil</term>
<term>Elderly</term>
<term>Enzyme inhibitor</term>
<term>Health</term>
<term>Improvement</term>
<term>Maintenance</term>
<term>Patient</term>
<term>Piperidine derivatives</term>
<term>Senile dementia</term>
<term>Severe</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Amélioration</term>
<term>Santé</term>
<term>Personne âgée</term>
<term>Démence sénile</term>
<term>Donépézil</term>
<term>Maintenance</term>
<term>Activité</term>
<term>Vie quotidienne</term>
<term>Malade</term>
<term>Grave</term>
<term>Démence Alzheimer</term>
<term>Aidant</term>
<term>Acetylcholinesterase</term>
<term>Anticholinestérasique</term>
<term>Inhibiteur enzyme</term>
<term>Pipéridine dérivé</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Personne âgée</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">OBJECTIVES: This study investigated the efficacy of donepezil treatment on activities of daily living (ADLs) and social functioning in patients with moderate to severe Alzheimer's disease (AD) and the possible benefits of this treatment on caregiving time and stress levels. DESIGN: Randomized, double-blind, placebo-controlled, multinational study. SETTING: Patients resided in the community or in assisted living facilities who did not require skilled 24-hour nursing care. PARTICIPANTS: Two hundred ninety patients with moderate to severe AD (baseline standardized Mini-Mental State Examination score of 5-17). INTERVENTION: Donepezil (5 mg/d for 4 weeks and 10 mg/d per clinician's judgment thereafter) or placebo for 24 weeks. MEASUREMENTS: ADLs were assessed using the Disability Assessment for Dementia (DAD), the modified instrumental activities of daily living (IADL) scale (IADL+), and the modified Physical Self Maintenance Scale (PSMS+). Caregiver time spent assisting patients with basic and instrumental ADLs was recorded as part of the IADL+ and PSMS+ scales. Patients' social behavior was evaluated through the use of a caregiver diary that captured observations of patients' motivation, interactions, and engagement. Caregivers were evaluated for their levels of caregiver stress with a modified, multiple-item Caregiver Stress Scale (CSS). For each outcome measure, the mean change from baseline at Week 24 using a last observation carried forward (LOCF) analysis was calculated. RESULTS: IADL+ and PSMS+ mean change from baseline scores for donepezil-treated patients showed a slower decline during the study than placebo-treated patients (Week 24 LOCF mean treatment differences: IADL + = 6.83, P <.0001; PSMS+ = 1.32, P =.0015). Significant differences between the groups in favor of donepezil were observed on the DAD for instrumental and basic ADLs and on the three components required for the completion of each ADL: initiation, planning and organization, and effective performance. At baseline, caregivers of patients treated with donepezil (n = 141) did not differ significantly from caregivers of patients treated with placebo (n = 146) with respect to demographics or mean total scores on the CSS. At Week 24 LOCF, the overall distribution of caregiver ratings on each of the three caregiver diary items favored donepezil-treated patients over placebo-treated patients (P <.005). At Week 24 LOCF, mean change from baseline scores for CSS total and individual domain scores (all domains except caregiving competence, personal gain, and management of distress) were better for caregivers of donepezil-treated patients than for those of placebo-treated patients (CSS total, mean treatment difference = 1.82). Caregivers of donepezil-treated patients reported spending less time assisting with ADLs than caregivers of placebo-treated patients (mean difference = 52.4 min/d). CONCLUSION: Donepezil demonstrated a significantly slower decline than placebo in instrumental and basic ADLs in these patients with moderate to severe AD. The ADL benefits in AD patients treated with donepezil were associated with less caregiving time and lower levels of caregiver stress.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-8614</s0>
</fA01>
<fA03 i2="1"><s0>J. Am. Geriatr. Soc.</s0>
</fA03>
<fA05><s2>51</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>efficacy of Donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on Caregiver burden</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>FELDMAN (Howard)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GAUTHIER (Serge)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HECKER (Jane)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>VELLAS (Bruno)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>EMIR (Birol)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MASTEY (Vera)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SUBBIAH (Ponni)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Neurology, UBC Hospital, Clinic for Alzheimer's Disease and Related Disorders</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Alzheimer Disease Research Unit, McGill Center for Studies in Aging</s1>
<s2>Verdun, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Rehabilitation and Aged Care, Repatriation General Hospital</s1>
<s2>Daw Park, SA</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Toulouse University Alzheimer's Center</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Clinical Data Operations</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Clinical Data Operations and Outcomes Research, Pfizer, Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Clinical Data Operations and Pfizer Pharmaceuticals Group, Pfizer, Inc.</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>The Donepezil MSAD Study Investigators Group</s1>
<s3>INT</s3>
</fA17>
<fA20><s1>737-744</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>8328</s2>
<s5>354000118407420010</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0440479</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of the American Geriatrics Society</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>OBJECTIVES: This study investigated the efficacy of donepezil treatment on activities of daily living (ADLs) and social functioning in patients with moderate to severe Alzheimer's disease (AD) and the possible benefits of this treatment on caregiving time and stress levels. DESIGN: Randomized, double-blind, placebo-controlled, multinational study. SETTING: Patients resided in the community or in assisted living facilities who did not require skilled 24-hour nursing care. PARTICIPANTS: Two hundred ninety patients with moderate to severe AD (baseline standardized Mini-Mental State Examination score of 5-17). INTERVENTION: Donepezil (5 mg/d for 4 weeks and 10 mg/d per clinician's judgment thereafter) or placebo for 24 weeks. MEASUREMENTS: ADLs were assessed using the Disability Assessment for Dementia (DAD), the modified instrumental activities of daily living (IADL) scale (IADL+), and the modified Physical Self Maintenance Scale (PSMS+). Caregiver time spent assisting patients with basic and instrumental ADLs was recorded as part of the IADL+ and PSMS+ scales. Patients' social behavior was evaluated through the use of a caregiver diary that captured observations of patients' motivation, interactions, and engagement. Caregivers were evaluated for their levels of caregiver stress with a modified, multiple-item Caregiver Stress Scale (CSS). For each outcome measure, the mean change from baseline at Week 24 using a last observation carried forward (LOCF) analysis was calculated. RESULTS: IADL+ and PSMS+ mean change from baseline scores for donepezil-treated patients showed a slower decline during the study than placebo-treated patients (Week 24 LOCF mean treatment differences: IADL + = 6.83, P <.0001; PSMS+ = 1.32, P =.0015). Significant differences between the groups in favor of donepezil were observed on the DAD for instrumental and basic ADLs and on the three components required for the completion of each ADL: initiation, planning and organization, and effective performance. At baseline, caregivers of patients treated with donepezil (n = 141) did not differ significantly from caregivers of patients treated with placebo (n = 146) with respect to demographics or mean total scores on the CSS. At Week 24 LOCF, the overall distribution of caregiver ratings on each of the three caregiver diary items favored donepezil-treated patients over placebo-treated patients (P <.005). At Week 24 LOCF, mean change from baseline scores for CSS total and individual domain scores (all domains except caregiving competence, personal gain, and management of distress) were better for caregivers of donepezil-treated patients than for those of placebo-treated patients (CSS total, mean treatment difference = 1.82). Caregivers of donepezil-treated patients reported spending less time assisting with ADLs than caregivers of placebo-treated patients (mean difference = 52.4 min/d). CONCLUSION: Donepezil demonstrated a significantly slower decline than placebo in instrumental and basic ADLs in these patients with moderate to severe AD. The ADL benefits in AD patients treated with donepezil were associated with less caregiving time and lower levels of caregiver stress.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B09B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Amélioration</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Improvement</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Mejoría</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Santé</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Health</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Salud</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Personne âgée</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Elderly</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Anciano</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Démence sénile</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Senile dementia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Demencia senil</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Donépézil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Donepezil</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Donepezilo</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Maintenance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Maintenance</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mantenimiento</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Activité</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Activity</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Actividad</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Vie quotidienne</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Daily living</s0>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Vida cotidiana</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Malade</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Patient</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Enfermo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Grave</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Severe</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Grave</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Démence Alzheimer</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Alzheimer disease</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Demencia Alzheimer</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Aidant</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Caregiver</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Ayudante a domicilio</s0>
<s5>21</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Acetylcholinesterase</s0>
<s2>FE</s2>
<s5>22</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Acetylcholinesterase</s0>
<s2>FE</s2>
<s5>22</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Acetylcholinesterase</s0>
<s2>FE</s2>
<s5>22</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Anticholinestérasique</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Anticholinesterase agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Anticolinesterasa agente</s0>
<s5>23</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>24</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Pipéridine dérivé</s0>
<s5>35</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Piperidine derivatives</s0>
<s5>35</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Piperidina derivado</s0>
<s5>35</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Carboxylic ester hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Esterases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Esterases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Esterases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>48</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>48</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>48</s5>
</fC07>
<fN21><s1>300</s1>
</fN21>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000F24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:03-0440479 |texte= efficacy of Donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on Caregiver burden }}
This area was generated with Dilib version V0.6.33. |